Genzyme's Mozobil receives CHMP endorsement
This article was originally published in Scrip
The EU's CHMP has recommended the marketing approval of Genzyme's stem cell transplantation primer Mozobil (plerixafor), for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells from the bone marrow into the bloodstream for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.